title: [Clinical outcomes of lamivudine therapy and HLA alleles in chronic hepatitis B patients].
abstract: OBJECTIVE
  The human leukocyte antigen (HLA) system is an integral component of immune response. Highly polymorphic HLA genes may play a pivotal role in the response of antiviral therapy. We investigated the effects of HLA gene polymorphism on the clinical outcome of chronic hepatitis B patients who received lamivudine treatment.
  
  
  METHODS
  Depending on their clinical response to lamivudine therapy, a total of sixty one patients were divided into following groups; non-responders, viral breakthroughers, relapsers, and seroconverters. HLA-A, -B, -Cw, -DRB and HLA-DRB1 alleles typing was performed on each group through the polymerase chain reaction and the sequence-specific oligonucleotide hybridization method. The distribution patterns of HLA-A, HLA-B, HLA-Cw, HLA-DRB, and HLA-DRB1 were then analysed.
  
  
  RESULTS
  When non-responders were compared to the other groups, high frequencies in HLA-Cw1, HLA-DRB14 and HLA-DRB4 (p=0.015, 0.033 and 0.004 respectively) were evident. When seroconverters were compared to viral breakthroughers, high frequencies in HLA-A2 and HLA-DRB4 (p=0.048, 0.025 respectively) were evident.
  
  
  CONCLUSIONS
  Our data suggests that HLA-A2, HLA-Cw1, HLA-DRB14 genes are related to the clinical outcomes of lamivudine treatment in chronic hepatitis B patients. These genes may be used in the prediction of the clinical outcome of lamivudine therapy in chronic hepatitis B patients.
authors.affiliation: Department of Internal Medicine, Seoul Medical Center, Seoul, Korea.
authors.forename: Ji Min
authors.initials: JM
authors.lastname: Oh
authors.forename: Kyu Heum
authors.initials: KH
authors.lastname: Kwon
authors.forename: Jang Eon
authors.initials: JE
authors.lastname: Kim
authors.forename: Jin Ho
authors.initials: JH
authors.lastname: Choi
authors.forename: Sun Hee
authors.initials: SH
authors.lastname: Beom
authors.forename: Sang Hyuk
authors.initials: SH
authors.lastname: Lee
authors.forename: Yong Jik
authors.initials: YJ
authors.lastname: Lee
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Park
authors.forename: Mee Kyung
authors.initials: MK
authors.lastname: Jung
authors.forename: Kye Heui
authors.initials: KH
authors.lastname: Lee
mesh_terms: D000328:Adult; D000483:Alleles; D000998:Antiviral Agents / Q000008:administration & dosage*; D024882:Drug Resistance, Viral; D005260:Female; D020022:Genetic Predisposition to Disease; D006680:HLA Antigens / Q000235:genetics*; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006680:HLA Antigens; D019259:Lamivudine